Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study. (PubMed, Breast Cancer) - Oct 7, 2026 - "Both co-primary analyses showed an association with longer overall survival for ribociclib, with attenuation in the calendar-restricted analysis (HR 0.90, 95% CI 0.82-0.99). These findings are hypothesis-generating, not evidence of superiority, and require randomized confirmation."
HEOR • Journal • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • HER-2
|
|
Cho-Hao Lee; Hong-Jie Jhou; Hsin-Yu Chen; Li-Ting Kao; Ming-Shen Dai; Na Xiao; Po-Huang Chen; Tina Yi-Jin Hsieh; Wei-Cheng Chang; Xiaoyi Zhang
|